Start-Up Says A.I. Designed a Virus to Attack One Patient's Superbug
If the claim holds up, personalized phage therapy could become a new frontline weapon against antibiotic resistance - but proof is far from final.

Loading the Newsroom
Curating from trusted global sources…
15 briefings · “final”
If the claim holds up, personalized phage therapy could become a new frontline weapon against antibiotic resistance - but proof is far from final.
A final call from Beijing puts high-net-worth individuals on notice: declare offshore trust gains by October 22 or face penalties, with ripple effects for Hong Kong's wealth hub.
Google's premium ChromeOS-Android hybrid starts at $899, but the first major review says the software can't match the hardware. A risky debut against the MacBook Air and Surface Laptop.
The Tel Aviv startup's code execution model formally verifies optimizations, turning AI into an agent for the hardware itself.
MIT team traces APOE4's damage to lipid droplets, opening a new drug target beyond amyloid and tau.
The documentary about Elizabeth Holmes' final days before prison opened in under 1,000 theaters and still pulled $15 million.
Apple's first foldable starts at $1,999, and preorder demand is so strong that orders are slipping into 2027, reshaping the foldable market and your upgrade cycle.
The next-gen Roadster finally arrives with a thruster option, but the price of entry is steep enough to make even collectors blink.
The long-promised Roadster finally performed live, using cold-gas thrusters to clear Tesla's own lineup in a single bound.
David Ellison's studio avoids a March trial and a $7M-a-day ticking fee by settling with state AGs over local job losses.
After 15 years, Tim Cook hands Apple to John Ternus - here's how he turned a $350B company into a $4.6T juggernaut.
The fast-fashion giant finally listed in Hong Kong on Tuesday, but investors greeted it with a sell-off. Here's what the debut signals for the company and the broader market.